TRVN - Trevena Inc

-

$undefined

N/A

(N/A)

Trevena Inc OTC Markets OTCPK:TRVN Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Location: 955 Chesterbrook Boulevard, Chesterbrook, PA, 19087, United States | Website: https://www.trevena.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

25.18M

Cash

13.46M

Avg Qtr Burn

-6.773M

Short % of Float

7.30%

Insider Ownership

0.49%

Institutional Own.

9.99%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Phase 2

Initiation

TRV045 (S1P receptor) Details
Epilepsy, Central nervous system illness, Pain

Phase 1

Data readout

Failed

Discontinued

TRV027 (AT1 receptor selective agonist) Details
Acute respiratory distress syndrome, Infectious disease, COVID-19

Failed

Discontinued